Replimune (REPL) Gains on Positive Data From Melanoma Study

The anti-PD1 failed melanoma cohort from the IGNYTE clinical trial included 140 patients. These patients received RP1 plus Opdivo after confirmed progression while being treated with at least eight weeks of prior anti-PD1 therapy. The primary analysis by independent central review was triggered once all patients had been followed for at least 12 months. Data presented at the ASCO showed that approximately one-third of patients experienced a response, with an ORR by investigator assessment of 32.7%. Image So ...